Heterometallic titanium–gold complexes inhibit renal cancer cells in vitro and in vivo-Reference-Cited by-同舟云学术

Heterometallic titanium–gold complexes inhibit renal cancer cells in vitro and in vivo

Published:2015 Issue:9 Volume:6 Page:5269-5283
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Fernández-Gallardo Jacob¹²³⁴⁵^ORCID,Elie Benelita T.¹²³⁴⁵,Sadhukha Tanmoy⁶⁷⁸⁵,Prabha Swayam⁶⁷⁸⁵⁹,Sanaú Mercedes¹⁰¹¹¹²¹³,Rotenberg Susan A.¹⁴¹⁵³¹⁶⁵,Ramos Joe W.¹⁷¹⁸¹⁹²⁰⁵,Contel María¹²³⁴⁵^ORCID

Affiliation:

1. Department of Chemistry

2. Brooklyn College and The Graduate Center

3. The City University of New York

4. Brooklyn

5. USA

6. Department of Pharmaceutics

7. College of Pharmacy

8. University of Minnesota

9. Center for Translational Drug Delivery

10. Departamento de Química Inorgánica

11. Universidad de Valencia

12. Valencia

13. Spain

14. Biology PhD Program

15. The Graduate Center

16. New York

17. Cancer Biology Program

18. University of Hawaii Cancer Center

19. University of Hawaii at Manoa

20. Honolulu

Abstract

Heterometallic compounds as anticancer agents demonstratingin vivopotential for the first time. Titanocene–gold derivatives: promising candidates for renal cancer.

Funder

National Cancer Institute

National Science Foundation

National Institute of General Medical Sciences

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2015/SC/C5SC01753J

Reference77 articles.

1. Noble metals in medicine: Latest advances